IGFBP3 and metastatic malignant neoplasm in the lymph nodes: Therefore, we not only identified a new therapeutic biomarker for CC patients with lymph node metastasis but also provided a novel regulatory molecular mechanism involving cholesterol reprogramming and PDGF-AA/IGFBP-3 secretion (Fig. 8).